Compare Merck & Co., Inc. (MRK) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Abrdn Physical Platinum Shares ETF — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while Abrdn Physical Platinum Shares ETF trades at $14.8. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Abrdn Physical Platinum Shares ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| MRK | PPLT | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.52 | $25.23 |
52-Week Low | $77.60 | $11.78 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.47, down 0.21% on the day, amid a predominantly bearish technical signal with moving averages indicating strong selling pressure. The fund, which holds physical platinum, has seen significant volatility, with recent news highlighting its underperformance compared to gold and silver. A 10-for-1 stock split is scheduled for May 2026, which will adjust the share count without altering the fund's net asset value.
The outlook for PPLT is cautious, with technical indicators leaning bearish and sentiment mixed after a substantial rally. Investment opportunity hinges on a potential catch-up trade if platinum gains favor, but risks include commodity price swings and the ETF's lack of dividends, which may deter income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
